BridgeBio Oncology Therapeutics Inc.
BBOT
NASDAQ·Healthcare·Biotechnology·Mkt cap $700.1M
$8.74
▼ -4.79%
P/E
—
Mkt Cap
$700.1M
52-Wk Range
$7.00–$14.87
52-Week Range
$7.00 - $14.87
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 8.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary platform targeting prevalent oncogenic pathways (KRAS and PI3K)
- Experienced leadership team with strong oncology development track record
- Recent substantial capital raise ($450M) enabling robust clinical advancement
- Focused pipeline approach with multiple clinical-stage programs
Bear Case
1 risk
- Low volatility (beta 0.4).
Growth
Stable outlook
Advancement of clinical-stage programs through late-stage development phases
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Stable
-2.6% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying BBOT right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 11, 2026
AUG 11, 2026
Reported EPS of -$0.71 vs -$0.57 consensus (-24.8% surprise).
EPS surprise · last 4Q
0 of 2 beats
Estimate
Actual
Q3 26
-24.8%
Q2 26
-2.8%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: UBS · Jul 8, 2026
vs Industry
How BBOT stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related